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Abstract
In vivo models of Inflammatory Bowel Diseases (IBD) elucidate important mechanisms of chronic inflammation. Complex
intestinal responses to food components create a unique “fingerprint” discriminating health from disease. Five-week-old IL10−/− and
C57BL/6J (C57; control) mice were inoculated orally with complex intestinal microflora (CIF) and/or pure cultures of Enterococcus
faecalis and E. faecalis (EF) aiming for more consistent inflammation of the intestinal mucosa. Inoculation treatments were compared
to non-inoculated IL10−/− and C57 mice, either kept in specific pathogen free (SPF) or conventional conditions (2 × 5 factorial
design). At 12 weeks of age, mice were sacrificed for intestinal histological (HIS) and transcriptomic analysis using limma and
Ingenuity Pathway Analysis Software. Colonic HIS was significantly affected (P < 0.05) in inoculated IL10−/− mice and accounted
for approximately 60% of total intestinal HIS. Inoculation showed a strong effect on colonic gene expression, with more than
2000 genes differentially expressed in EF·CIF-inoculated IL10−/− mice. Immune response gene expression was altered (P < 0.05)
in these mice. The second study investigated the effect of arachidonic (AA) and eicosapentaenoic acid (EPA) on colonic HIS and
gene expression to test whether EPA, contrary to AA, diminished intestinal inflammation in EF·CIF IL10−/− mice (2 × 4 factorial
design). AIN-76A (5% corn oil) and AIN-76A (fat-free) +1% corn oil supplemented with either 3.7% oleic acid (OA), AA or EPA
were used. IL10−/− mice fed EPA- and AA-enriched diets had at least 40% lower colonic HIS (P < 0.05) than those fed control
diets (AIN-76A and OA diets). The expression of immune response and ‘inflammatory disease’ genes (down-regulated: TNF, IL6,
S100A8, FGF7, PTGS2; up-regulated: PPAR, MGLL, MYLK, PPSS23, ABCB4 with EPA and/or AA) was affected in IL10−/−
mice fed EPA- and AA-enriched diets, compared to those fed AIN-76A diet.
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1. Introduction
The intestinal tract is the largest interface where
human beings interact with their environment. This com-
plex system consists of different cell types, harbors up
to 1013 bacteria – more than 10 times the number of
cells in the body [1] – and comprises 70% of the body’s
immune system [2]. Four protective barriers maintain the
integrity of this interface: the epithelial barrier [3], the
chemical barrier [4], the microbiological barrier [1] and
the immunological barrier [5,6]. The disruption of one
or more of these barriers can lead to chronic inflamma-
tion which is a hallmark of intestinal disorders such as
Ulcerative Colitis [7] and Crohn’s Disease [8,9], collec-
tively referred to as Inflammatory Bowel Diseases (IBD).
Current in vitro models, while useful for screening com-
ponents, are unable to mimic the level of complexity
of the intestinal system. Thus, in vivo models of IBD
are important for unraveling the complex interactions
between food, intestinal bacteria and intestinal cells,
thereby elucidating the mechanisms by which IBD are
initiated and maintained.
While the exact etiology and pathogenesis of IBD
is still unclear, there is strong epidemiological evidence
for a genetic contribution to disease susceptibility. Since
IL10−/− mice spontaneously develop intestinal entero-
colitis, they have been used extensively as a model of
IBD [10–12]. IL10 is an anti-inflammatory cytokine
which affects the growth and differentiation of vari-
ous cell types of the immune system in vitro [13] and
suppresses their function by inhibiting production of
numerous cytokines by these cells [14]. Thus, IL10 is
an important regulator of intestinal mucosal responses
[15]. The severity of enterocolitis in IL10−/− mice is
dependent on the breeding background, with BALB/c
mice showing the most severe symptoms and C57BL/6J
the least severe [16]. In the case of the latter, IL10−/−
mice develop CD-like colitis by 12 weeks of age but
this is not the case when they are raised under specific
pathogen free (SPF) conditions [16]. Other studies report
that under SPF conditions, IL10−/− mice do develop
colitis, but it is less severe and is not observed before
20 weeks of age [17]. The mechanistic defect causing
inflammation in IL10−/− mice is unclear but intestinal
bacteria are necessary for the initiation and progression
of inflammation [18].
Results from our laboratory using IL10−/− mice
(C57BL/6J background) showed individual variability
between animals with respect to the occurrence and
severity of intestinal inflammation [19]. In the first part
of this paper, we describe an experiment in which the
effect of inoculation with intestinal bacteria was tested
in IL10−/− mice to determine whether this would result
in a more consistent and reproducible mucosal inflam-
mation in the intestine. Histological injury score and
gene expression in intestinal tissues of IL10−/− mice ino-
culated with populations of bacteria commonly found in
the intestinal lumen, either complex intestinal microflora
(CIF) and/or pure cultures of intestinal bacteria such
as Enterococcus faecalis and E. faecium (EF) [20],
were measured. These bacteria were introduced into the
intestinal tract at a similar level to wild-type animals in
normal conditions, with the aim of ensuring that bacte-
rial colonization and subsequent exposure to potential
inflammatory factors occurred at a similar level across
all treatments.
In the second part of this paper, preliminary findings
on the effect of two polyunsaturated fatty acids (PUFA),
arachidonic (AA) and eicosapentaenoic acid (EPA), on
intestinal inflammation are presented. AA is a precursor
for the synthesis of eicosanoids, which are modulators
of defensive and inflammatory processes in the intestinal
mucosa [21]. EPA can inhibit AA metabolism competi-
tively via the cyclo-oxygenase enzymatic pathways and
thereby suppress the production of AA inflammatory
mediators [21]. We hypothesize that contrary to AA, EPA
diminishes both the severity of the lesions and the pro-
gression of induced intestinal inflammation. The aim was
to identify these interactions using bacterially inoculated
IL10−/− mice, with principal outcomes being histolo-
gical injury score and differential gene expression using
transcriptomic analysis.
2. Material and methods
The experimental procedures for these trials were reviewed
and approved by the Crown Research Institute Animal Ethics
Committee in Hamilton, New Zealand, according to the Ani-
mal Protection Act (1960) and Animal Protection Regulations
(1987) and amendments.
2.1. Animals
Male mice, 4–5 weeks of age were used for all exper-
iments. IL10−/− mice (B6.129P2-IL10 < tm1Cgn > /J) and
C57 controls (C57BL/6J) were purchased from the Jackson
Laboratory (Bar Harbor, Maine, USA), and individually
housed under conventional conditions (12-h light:12-h dark
cycle (lights on from 08:00 to 20:00 h), temperature of
22 ± 1 ◦C and approximately 50% relative humidity) in
shoebox-style cages containing untreated wood shavings (Hi
Tech Security Disposals Ltd., Auckland, New Zealand) and
a plastic tube for environmental enrichment. All mice were
given water and, unless otherwise stated, fed a non-sterile,
AIN-76A powdered diet made in-house (Table 1). Food intake
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Table 1
Composition of the AIN-76A diet and the AIN-76A diets enriched
with oleic acid (OA), arachidonic acid (AA) and eicosapentaenoic acid
(EPA)
Dietary ingredient Percentage in the diet
AIN-76A OA EPA AA
Caseina 20 20 20 20
DL-methionineb 0.3 0.3 0.3 0.3
Sucrosec 50 50 50 50
Dextrind 15 15 15 15
Arbocel, non-nutritive bulke 5 5 5 5
Corn oilf 5 1 1 1
C18:2, 99%+g 0 0.20 0.20 0.20
C18:3, 99%+h 0 0.06 0.06 0.06
Oleic acid, 99%+ 0 3.74 0 0
Eicosapentaenoic acid, 98%+ 0 0 3.74 0
Arachidonic acid, 99%+ 0 0 0 3.74
Choline bitartrateb 0.2 0.2 0.2 0.2
AIN-76A Mineral Mixi 3.5 3.5 3.5 3.5
AIN-76A Vitamin Mixi 1 1 1 1
Ethoxyquinb 0.01 0 0 0
TBHQj 0 0.001 0.001 0.001
All diets were prepared in-house using ingredients from the suppliers
listed, and according to the compositions shown.
a Alacid, lactic casein 30 mesh, NZMP Ltd., Wellington, New
Zealand.
b Sigma, Sigma–Aldrich Inc., St. Louis, MO, USA.
c Caster sugar, Chelsea, New Zealand Sugar Company Limited,
Auckland, New Zealand.
d Wheaten cornstarch, Golden Harves, Primary Foods Ltd., Auck-
land, New Zealand.
e Arbocell B600, J. Rettenmaier & Sohne GmbH+ Co, Rosenberg,
Germany.
f Tradewinds, Davis Trading, Palmerston North, New Zealand.
g C18:2, linoleic acid.
h C18:3, alpha-linolenic acid.
i Prepared in-house based on the AIN-76A diet formulation [46].
j TBHQ, Tertiary butylhydroquinone as antioxidant.
was measured daily and water was refreshed twice a week. The
food intake of all mice was adjusted daily to equal the mean
amount of food consumed by the IL10−/− mice on the previous
day. Growth performance was measured a minimum of thrice
weekly. All mice were carefully monitored for disease symp-
toms (weight loss, soft faeces, inactivity). Tissue sampling and
downstream analyses were performed as described below.
2.2. Inoculation study in IL-10−/− mice
Twenty-five male C57 mice and 25 male IL10−/− mice
(C57BL/6J background) were used (Fig. 1). Upon arrival (4
weeks of age), five C57 and five IL10−/− mice were housed
in SPF conditions (isolator cages). All mice were fed AIN-
76A powdered diet (Table 1) sterilized by gamma radiation
suitable for SPF (Schering-Plough, Wellington, New Zealand).
The other 20 C57 and 20 IL10−/− mice were housed in con-
ventional conditions. At 5 weeks of age, 15 of each strain were
inoculated orally with the three different preparations of bac-
teria commonly found in the intestinal lumen (5 IL10−/− mice
and 5 C57 mice each for each different bacterial preparation).
Five C57 mice and five IL10−/− mice housed in conven-
tional conditions were inoculated with a culture of E. faecalis
and E. faecium (EF; 12 calf and chicken strains obtained
from AgResearch Microbiology Group in Palmerston North;
1.2 × 108 colony forming units). The Enterococcus strains
were subcultured onto fresh Slanetz & Bartley medium (Oxoid,
Hampshire, UK) and incubated at 42 ◦C for 48 h, then trans-
ferred to Todd-Hewitt Broth (Oxoid, Hampshire, UK) and
incubated at 37 ◦C for 24 h. All strains were then centrifuged
(2000 × g, 10 min, 4 ◦C), re-suspended in sterile 1× PBS, and
pooled for inoculation.
Another five C57 and five IL10−/− mice were inoculated
with complex intestinal flora (CIF; 200 L). The CIF solu-
tion was prepared by harvesting digesta from age-matched
C57BL/6 mice raised under conventional conditions following
humane euthanasia by CO2 asphyxiation and cervical dislo-
cation. Briefly, the intestinal tract (from pyloric sphincter to
caecum) was removed and digesta were collected from the
intestine and caecum and suspended in sterile 1× PBS.
The final group of five C57 and five IL10−/− mice was
inoculated with 200 L of an inoculation solution consisting
of a 1:1 (v/v) mixture of the EF (6.0 × 107 CFU) and CIF
solutions described above (EF·CIF).
The EF, CIF and EF·CIF treatments were compared with
each other and to non-inoculated C57 and IL10−/− mice and
C57 and IL10−/− mice kept in SPF according to a 2 × 5 fac-
torial design. At 12 weeks of age, all mice were sacrificed
and sampling performed to harvest tissues and body fluids for
histology evaluation and transcriptomic analysis of intestinal
tissues as described below.
2.3. PUFA experiment with IL10−/− mice
Twenty-four male C57 mice and 24 male IL10−/− mice
were inoculated according to the EF·CIF protocol described
above to obtain consistent and reproducible intestinal inflam-
mation. A powdered diet based on AIN-76A (Table 1) was
used to facilitate the mixing of EPA and AA compounds.
Mice were randomly assigned to the following diets (Table 1)
according to a 2 × 4 factorial design: (1) AIN-76A (5% corn
oil), (2) AIN-76A (fat-free) + 1% corn oil + 3.7% oleic acid
(OA), (3) AIN-76A (fat-free) + 1% corn oil + 3.7% AA and
(4) AIN-76A (fat-free) + 1% corn oil + 3.7% EPA (Fig. 1). The
1% corn oil was supplemented with purified linoleic acid and
alpha-linolenic acid to meet the nutritional requirements of
mice for these essential fatty acids [22]; the OA, EPA and AA
diets had 5% fat as in the AIN-76A diet. The ethyl ester of OA
was used to make an OA-enriched control diet so that AA and
EPA in PUFA-enriched diets could be substituted for OA. OA
was chosen as the control fatty acid because it has no effect on
tissue contents of AA and EPA and on eicosanoid biosynthesis
[23]. Esters of AA, OA, linoleic acid and alpha-linolenic acid
(99% purity, NuCheck Inc., Elysian, MN, USA) and EPA (98%
purity, Brainfats Biotechnology Limited, Auckland, New
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Fig. 1. Overall study design, showing the inoculation (a) and PUFA (b) experiments. For both experiments, mice were fed experimental diets from
4.5 weeks of age. In the case of the inoculation study, the diet was AIN-76A for all groups, while for the PUFA trial the diets are as shown in
the figure and described in Table 1. Inoculation was performed at 5 weeks of age; for the inoculation experiment, this was as described in Section
2.2, while for the PUFA experiment all animals were inoculated with a mixture of Enterococcus faecalis and Enterococcus faecium strains and
conventional intestinal flora derived from normal C57BL/6 mice raised under conventional conditions (EF·CIF). Tissue sampling was performed at
11 and 12 weeks of age, respectively, for the PUFA and inoculation experiments.
Zealand) were used. Between 5 and 11 weeks of age food con-
sumption and growth performance were recorded as described
previously. At 11 weeks of age, all mice were sacrificed and
sampling performed to harvest tissue and body fluids for
histology evaluation and transcriptomic analysis of intestinal
tissues as described below. This tissue sampling time was
selected based on a previous study, where IL10−/− mice inoc-
ulated with EF·CIF at 5 weeks of age showed an acceptable
and consistent level of colonic inflammation by 11 weeks of
age [24].
2.4. Tissue sampling
Before sacrifice, mice were fasted overnight (14 h), after
which food was re-offered for 2 h. Food was again removed
for the 2 h prior to sampling. This was to minimize the varia-
tion in time between the last food intake and tissue sampling
[25]. A maximum of 12 mice were euthanized on each day; 14 h
overnight fasting and tissue sampling were staggered in three
groups of four mice, with 1 h between each group. Animals
were euthanized via CO2 asphyxiation and cervical disloca-
tion. Blood was sampled via cardiac puncture (0.5–1 mL), and
cells were separated from plasma by centrifugation (2000 × g,
3 min, room temperature). Plasma was removed, immediately
frozen in liquid nitrogen and stored at −85 ◦C. Pelleted blood
cells were re-suspended in RNAlater® (Ambion, Austin, TX,
USA) and frozen for subsequent RNA extraction. Spleen, liver,
thymus, kidneys and skeletal muscle were quickly removed and
frozen in liquid nitrogen. The intestine was quickly removed,
cut open lengthwise and flushed with 0.9% NaCl to remove any
traces of digesta, then carefully laid out on an ice cold stainless
steel tray. Sections of duodenum, jejunum, ileum and colon
were fixed in 10% phosphate-buffered formalin and stored at
room temperature until histological evaluation of inflamma-
tion. Samples of the same tissue were also rapidly frozen in
liquid nitrogen before storage at −85 ◦C for gene and protein
profiling.
2.5. Histopathology
Formalin-fixed intestinal tissue samples were embedded
in paraffin and processed for sectioning [26]. Embedded
tissue samples were sliced to obtain 5 m thick sections
which were stained with haematoxylin and eosin for light
microscopic examination. Stained sections were assessed
for inflammation based on a combination of inflammatory
cell infiltration (monocytes, neutrophils, fibrin exudation
and lymphangiectasis), tissue destruction (oedema and
mucosal atrophy) and tissue repair (hyperplasia, angiogenesis,
granulomas and fibrosis) [26]. A rating score between 0 (no
change from normal tissue) and 3 (lesions involved most areas
and all the layers of the intestinal section including mucosa,
muscle and omental fat) was applied to each intestinal section
(ileum, colon, etc.) for each aspect of inflammation (e.g.
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monocytes, oedema, hyperplasia, etc.). The sum of scores
for inflammatory cell infiltration (multiplied by 2), tissue
destruction and tissue repair was used to represent the total
histological injury score (HIS) for each intestinal section.
The sum of the inflammatory cell infiltration was multiplied
by 2 to give more weight to this value, as this represented
the main characteristic of the observed inflammation. Gene
expression analysis was performed only if significant changes
in histopathology were observed in any intestinal section.
2.6. Gene expression hybridization
For microarray hybridization, total RNA from intestinal
tissues was isolated by homogenizing the samples in TRI-
zol (Invitrogen, Auckland, New Zealand), a modification of
the acid guanidinium thiocyanate–phenol–chloroform extrac-
tion method [27], according to the manufacturer’s instructions.
RNA was quantified with a Nanodrop ND-1000 spectropho-
tometer (NanoDrop Technologies, Wilmington, DE, USA),
and RNA integrity was assessed with an RNA 6000 Nano
LabChip kit using the Agilent 2100 Bioanalyser (Agilent
Technologies, Santa Clara, CA, USA). Extracted RNAs were
purified using RNeasy spin columns (QIAGEN, San Diego,
CA, USA). Only total RNA with an OD 260/280 ratio > 2.0, a
Bioanalyzer 28s/18s peak ratio > 1.2 and a RIN number supe-
rior to 8 was used for microarray hybridization. An equimolar
pool of two to three total RNA extracts from intestinal tissues
of two to three different mice per treatment was made. Ref-
erence RNA was used for microarray hybridization. For the
inoculation trial, RNA extracts from control and treated mice
were pooled in an equimolar proportion and used as the refer-
ence sample. For the PUFA trial, equimolar RNA extracts from
small intestine, colon, kidney and liver of normal healthy grow-
ing Swiss mice plus RNA extracts from Swiss mouse fetuses
were pooled to make a universal reference RNA for use in all
subsequent trials.
RNA samples (experimental and reference pools) were
labeled using the Agilent Low RNA Input Linear Ampli-
fication Kit (5184-3523) according to the manufacturer’s
instructions. Briefly, 500 ng of total RNA was amplified and
reverse transcribed in vitro to cDNA using T7-polymerase,
which was subsequently labeled with either cyanine3
(experimental) or cyanine5 (reference)-labeled CTP (10 mM;
Perkin-Elmer/NEN Life Science (NEL 580, 581), Boston,
MA, USA) dye. A Nanodrop ND-1000 spectrophotometer was
used to monitor dye incorporation for the experimental sam-
ples (500 ng) which was between 9 and 22 pmol/g. Targets
consisting of amplified and fluorescent-labeled cRNA were
hybridized using the Agilent oligonucleotide microarray in situ
hybridization plus kit (5184-3568), following the manufac-
turer’s protocols. Briefly 750 ng of pooled treatment cRNA was
mixed with 750 ng of pooled reference cRNA in the presence
of a control target, fragmented for 30 min at 60 ◦C in the dark
and hybridized onto Agilent Technologies 44k (G4122-60510)
mouse 60mer oligonucleotide arrays in a rotation oven (60 ◦C,
17 h, 4 rpm in the dark). Following hybridization, chambers
were disassembled and the slides sequentially washed in
solutions I, II and III (Agilent Technologies, Santa Clara, CA,
USA) and air-dried. Slides were then scanned using a GenePix
Professional 4200A scanner (Molecular Devices, Sunnyvale,
CA, USA); a photomultiplier tube voltage of 550 (red laser)
and 545 (green laser) was applied for the inoculation trial, and
a photomultiplier tube voltage of 585 (red laser) and 600 (green
laser) for the PUFA trial. Spot identification and quantification
was performed with GenePix 6.0 software (Molecular
Devices).
2.7. Statistical analysis
Statistical analyses of body weight and histological injury
score were performed in GenStat (eighth ed., VSN Interna-
tional, Hemel Hempstead, UK, 2005). One-way ANOVA was
used to detect significant differences between treatments. Log
transformed values were used for the statistical analysis of HIS
scores. A probability value less than 0.05 was regarded as si-
gnificant and probability less than 0.10 but higher than 0.05
was declared a trend.
Intensity ratio values for all microarray spots were norma-
lized using global lowess normalization without background
correction (inoculation trial) and with background correction
(PUFA trial). Relative amounts of the two dyes were used to
determine the level of expression of a particular gene in IL10−/−
mice compared to C57 mice. For each comparison a candi-
date list of differentially expressed genes was generated using
linear models for microarray analysis (limma) within the Bio-
conductor framework [28]. For IL10−/− versus C57 (control
diet) comparisons in both the inoculation and PUFA experi-
ments, moderated t-statistics and false discovery rate control
with probability less than 0.05- and 1.5-fold-change as statisti-
cal filtering criteria were used. For IL10−/− versus C57 (PUFA
diets) comparisons, moderated t-statistics and probability less
than 0.05- and 1.3-fold-change as statistical filtering criteria
were used due to fewer genes being differently expressed,
often with a lower fold-change compared to the inflamma-
tion comparison [28]. Differentially expressed genes from the
inoculation and PUFA experiments were clustered into path-
ways using Ingenuity Pathway Analysis (Ingenuity Systems
Inc., Redwood City, CA, USA).
This paper presents preliminary microarray results for both
the inoculation and PUFA trial. Validation of gene expression
changes is on-going; in this paper, only genes with a fold-
change in expression greater than 1.5-fold for the inoculation
trial and 1.3-fold for the PUFA experiment are presented. The
gene expression data presented in the tables represent diffe-
rentially expressed genes within a particular pathway ranked
in the first 1000 differentially expressed genes according to
the probability value obtained using limma analysis. PUFA
comparisons are shown for IL10−/− mice fed PUFA-enriched
diets and IL10−/− mice fed the AIN-76A diet. AIN-76A is the
diet common to both inoculation and PUFA experiments; any
reference to a control diet in Sections 3 and 4 applies to the
AIN-76A diet.
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3. Results
3.1. Inoculation trial
Mean live weight gain, measured between 5 and 10
weeks of age, was lower in IL10−/− mice compared to
C57 mice in the C and EF·CIF groups (Table 2). EF·CIF
inoculated IL10−/− mice and non-inoculated IL10−/−
mice kept in conventional condition (C group) gained
less weight than non-inoculated IL10−/− mice kept in
SPF and EF- or CIF-inoculated IL10−/− mice (Table 2).
For the C57 group, only the EF inoculation signifi-
cantly reduced (P < 0.05) live weight gain compared to
non-inoculated C57 mice either in SPF or conventional
conditions (Table 2). There was no difference in live
weight gain between the non-inoculated C57 mice kept
in SPF or conventional conditions (Table 2). All C57
mice inoculated with a bacterial preparation (EF, CIF or
EF·CIF) had the same live weight gain (Table 2).
There was no significant difference between the two
mouse strains with respect to total intestinal inflamma-
tion in the C group (IL10−/− 4.7 ± 3.0 (S.D.) versus C57
4.3 ± 1.4 (S.D.), P = 0.65). As a result of inoculation,
total intestinal HIS was higher in IL10−/− mice, and this
effect was significant in both the EF (IL10−/− 12.5 ± 5.9
(S.D.) versus C57 2.3 ± 1.3 (S.D.), P < 0.05) and EF·CIF
(IL10−/− 13.7 ± 5.4 (S.D.) versus C57 4.9 ± 2.3 (S.D.),
P < 0.05) groups. Colon was the most inflamed intestinal
section (Fig. 2a), accounting for approximately 60% of
total intestinal HIS in inoculated IL10−/− mice. Colon
HIS was greater in IL10−/− mice in each of the inoc-
ulation groups compared to C57 mice, with the largest
difference being in the EF·CIF group (IL10−/− 8.1 ± 3.8
(S.D.) versus C57 0.4 ± 0.5 (S.D.), P < 0.01; Fig. 2b).
Colon was therefore used for subsequent microarray
analysis.
Initial microarray limma analysis showed a strong
effect of inoculation on gene expression; 155 genes were
differentially expressed (fold-change > 1.5, P < 0.05)
in non-inoculated IL10−/− mice compared to non-
inoculated C57 mice. In contrast, approximately 2000
genes showed differential expression in EF- and EF·CIF-
inoculated IL10−/− mice compared to C57 mice with the
same inoculations. For the CIF inoculation, over 1700
genes showed differential expression in IL10−/− mice
compared to CIF-inoculated C57 mice. IL10−/− mice
inoculated with EF·CIF had the greatest number of dif-
ferentially expressed genes (2105) when compared with
non-inoculated IL10−/− mice (group C), followed by
EF (1641) and CIF (929). When the first 1000 ranked
differentially expressed genes were compared between
the three inoculation protocols using Ingenuity Pathway
Fig. 2. (a) Total intestinal histological injury score (HIS) and (b) colon
HIS of IL10−/− and C57 mice at 12 weeks of age after different inoc-
ulations at 5 weeks of age. Data represent mean for 5 mice fed the
AIN-76A diet, and housed in specific pathogen free (SPF) or con-
ventional (C) conditions, or housed in conventional conditions and
orally inoculated with 12 Enterococcus strains (EF), with conventional
intestinal flora from normal C57BL/6 mice (CIF), or a 1:1 combination
(EF·CIF) at 5 weeks of age. Error bar represents the least significant
differences (LSD) for the overall comparison of data.
Analysis, changes in gene expression were largely con-
sistent across the inoculation protocols (Table 3).
Clustering of the 155 differentially expressed genes
between IL10−/− and C57 mice in the C group using
Ingenuity Pathway Analysis identified lipid metabolism,
molecular transport and small molecule biochemistry
as the most significant pathways that were affected
(Table 3). In contrast, cellular movement, haemato-
logical system development and function and immune
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Table 2
Mean live weight gain (g) of IL10−/− and C57 mice between 5 and 10 weeks of age
Mouse strain Anova P-value (57 vs. IL10−/−)
C57 IL10−/−
Inoculation experimenta
SPF 5.40 ± 0.73a 4.76 ± 1.25a P = 0.49
C 5.94 ± 1.46a 1.98 ± 2.30b P < 0.05
EF 3.86 ± 0.79b 2.98 ± 3.29a,b P = 0.59
CIF 4.86 ± 3.04a,b 2.03 ± 1.86a,b P = 0.23
EF·CIF 5.26 ± 1.79a,b 2.12 ± 1.45b P < 0.01
PUFA experimentb
AIN-76A 6.09 ± 2.37a 4.85 ± 0.73a P = 0.36
OA 5.68 ± 1.87a 5.20 ± 0.92a P = 0.31
EPA 5.27 ± 0.34a 2.19 ± 1.36b P < 0.001
AA 3.82 ± 0.93b 3.70 ± 0.96c P = 0.41
a Data represent mean ± S.D. for 5 mice fed the AIN-76A diet, and housed in specific pathogen free (SPF) or conventional (C) conditions, or
housed in conventional conditions and orally inoculated with 12 Enterococcus strains (EF), with conventional intestinal flora from normal C57 mice
(CIF), or a 1:1 combination (EF·CIF). Superscript letters (a and b) denote C57 and IL10−/− mice with values significantly different from mice of
the same strain under SPF conditions.
b Data represent mean ± S.D. for six mice fed the AIN-76A diet, or AIN-76A diet supplemented with oleic acid (OA), or the PUFAs eicos-
apentaenoic acid (EPA) or arachidonic acid (AA). All mice were inoculated at 5 weeks of age with a combination of 12 Enteroccocus strains and
conventional intestinal flora from normal C57 mice. Superscript letters (a–c) that are different indicate a statistical difference (P < 0.05) between
IL10−/− mice fed AIN-76A, OA, EPA or AA diets and between C57 mice fed AIN-76A, OA, EPA or AA diets.
response were the most significant pathways altered in
IL10−/− mice as a result of the EF·CIF inoculation com-
pared to similarly inoculated C57 controls (Table 3).
Genes and fold-changes from the immune response,
‘inflammatory diseases’ and antigen presentation path-
ways are shown in Tables 4 and 5.
For the antigen presentation pathway, 12 genes
were up-regulated in IL10−/− mice as a result of
EF·CIF inoculation compared to C57 mice receiving
the same inoculation; no genes showed evidence of
down-regulation in this pathway (Table 5). In the case
of immune response, 140 genes were differentially
expressed in EF·CIF inoculated IL10−/− mice compared
to EF·CIF inoculated C57 mice. Only the genes within
this pathway that were differentially expressed with the
EPA- and/or AA-enriched diets are presented in Section
3.3 and in Table 4. For example, the ATP-binding
cassette sub-family B member 4 gene (ABCB4) and
S100 calcium binding protein A8 gene (S100A8), which
ranked in the top 30 according to its limma probability
value, are shown in Table 4. In comparison, only 13
immune response genes were differentially expressed
in non-inoculated IL10−/− mice compared to the non-
inoculated C57 mice (data not shown). Seventy-three
genes associated with the Ingenuity Pathway Analysis
grouping of ‘inflammatory diseases’ showed differential
expression in the EF·CIF IL10−/− mice compared
to EF·CIF C57 mice (including ABCB4, SLP1 and
TNFRSFIB; Table 4). This is contrasted with only six
genes differentially expressed genes in this pathway
for the non-inoculated IL10−/− mice compared to non-
inoculated C57 mice (C comparison; data not shown).
3.2. PUFA trial
Mean live weight gain from 5 to 10 weeks of age for
C57 and IL10−/− mice in the various dietary treatments
is shown in Table 2. Live weight gain was signifi-
cantly lower in IL10−/− mice fed the EPA-enriched
diet (P < 0.05) compared to IL10−/− mice fed the AA-
enriched diet (Table 2). Reduction in live weight gain
was also obtained when the IL10−/− mice fed the EPA-
enriched diet or AA-enriched diet was compared to the
control diets (AIN-76A and OA). There was no dif-
ference between IL10−/− mice fed either control diet
(Table 2). Within the C57 mice, there was no significant
difference in live weight gain between the AIN-76A, OA
and EPA diets but C57 mice fed the AA diet gained less
weight than C57 mice fed the AIN-76A, OA and EPA
diets (Table 2). There was no significant difference in
mean live weight gain between C57 and IL10−/− mice
in the AIN-76A, OA or AA diet groups but IL10−/−
mice fed the EPA-enriched diet had a reduced live
weight gain compared to C57 mice fed the same diet
(Table 2).
Total intestinal HIS among IL10−/− mice was higher
than for C57 mice (IL10−/− 9.3 ± 1.5 (S.D.) versus C57
1.3 ± 0.4 (S.D.), P < 0.01) with colon being the most
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Table 3
Summary of differentially expressed genes in colon tissue of IL-10−/− mice compared to C57 mice, and in IL10−/− mice inoculated with EF·CIF
in response to dietary PUFAs, and the key functions represented by these genes
Comparison Differentially expressed genes Major functions (number differentially expressed)
Increase Decrease Total
Inoculation experiment
C (IL10−/− vs. C57) 104 51 155
Lipid metabolism (11)
Molecular transport (7)
Small molecule biochemistry (18)
EF (IL10−/− vs. C57) 1020 1222 2242
Cellular movement (110)
Haematological system development and function (127)
Immune response (140)
CIF (IL10−/− vs. C57) 864 839 1703
Cellular movement (109)
Haematological system development and function (129)
Immune response (147)
EF·CIF (IL10−/− vs. C57) 967 1032 1999
Cellular movement (107)
Haematological system development and function (115)
Immune response (140)
IL10−/− (EF vs. C) 633 1008 1641
Cellular movement (98)
Haematological system development and function (104)
Immune response (120)
IL10−/− (CIF vs. C) 450 479 929
Immune response (127)
Cellular movement (110)
Haematological system development and function (116)
IL10−/− (EF·CIF vs. C) 604 1501 2105
Cellular movement (97)
Haematological system development and function (106)
Immune response (118)
PUFA experiment
AIN-76 (IL10−/− vs C57) 1046 889 1935
Inflammatory disease (94)
Haematological system development and function (121)
Immune response (143)
IL10−/− (OA vs. AIN-76A) 264 257 521
Cellular growth and proliferation (15)
Cell-to-cell signaling and interaction (31)
Immune response (10)
IL10−/− (EPA vs. AIN-76A) 597 389 986
Cell-to-cell signaling and interaction (42)
Inflammatory diseases (15)
Amino acid metabolism (4)
IL10−/− (AA vs. AIN-76A) 852 575 1427
Cell-to-cell signaling and interaction (79)
Inflammatory diseases (49)
Amino acid metabolism (8)
Data represent numbers of differentially expressed genes for each comparison, calculated using limma analysis within the Bioconductor framework.
For the inoculation experiment, a fold-change of >1.5 and false discovery rate control of P < 0.05 were used as filtering criteria; for the PUFA
experiment, fold-change >1.3 and P-value <0.05. The most significant functions were identified using Ingenuity Pathway Analysis Software. Total
RNA from colon tissue was used for microarray hybridization to Agilent Technologies 44k (G4122-60510) mouse 60mer oligonucleotide arrays.
For the inoculation (EF·CIF-inoculated IL10−/− vs. similarly treated C57 mice) and PUFA (PUFA-fed IL10−/− vs. AIN-76A-fed IL10−/− mice)
experiments data represent mean values from two pools of RNA for each mouse strain, with RNA from two and three mice, respectively, in each
pool.
inflamed intestinal tissue (Fig. 3a). Intestinal inflamma-
tion scores were mainly derived from inflammatory cell
infiltration (75%, monocytes and neutrophils) and to a
lesser extent, tissue destruction (20%, enterocyte loss
and edema) and tissue repair (5%, hyperplasia). IL10−/−
mice on the EPA and AA diets had at least 40% lower
colonic HIS scores (P < 0.05) than IL10−/− mice on con-
trol diets, AIN-76A and OA (Fig. 3b). There was also a
greater variation in HIS in the colon of IL10−/− mice
compared to C57 mice (Fig. 3b).
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Table 4
Differentially expressed immune response and ‘inflammatory diseases’ genes in colon tissue of IL-10−/− mice compared to C57 mice (both with
EF·CIF bacterial inoculation), and in PUFA-fed EF·CIF-inoculated IL10−/− mice compared to similarly inoculated IL10−/− mice fed AIN-76A







ATP-binding cassette, subfamily B, member
4
ABCB4 NM 008830 −4.1 +2.8 +1.7
Calpastatin CAST NM 009817 +1.9 +1.4 +1.3
CD38 molecule CD38 NM 007646 +3.3 +1.7NS +2.2
Fibroblast growth factor 7 FGF7 NM 008008 +1.1NS −1.3NS −1.6
Inducible T-cell costimulator ligand ICOSLG NM 015790 +1.1NS +1.4NS +1.6
Interleukin 6 IL6 NM 031168 −1.2NS −1.1NS −2.7
Monoglyceride lipase MGLL NM 011844 −2.3 +2.1 +1.8
Myosin, light polypeptide kinase MYLK NM 139300 −2.7 +1.4 +1.4
Peroxisome proliferative activated receptor,
alpha
PPAR NM 011144 −2.3 +1.9 +1.7
Peroxisome proliferative activated receptor,
gamma, coactivator 1, alpha
PPARGC1A AK032149 −1.2NS +1.3NS +1.4
Protease, serine, 23 PRSS23 NM 029614 −3.8 +2.0NS +2.8
Prostaglandin-endoperoxide synthase 2
(Cox-2)
PTGS2 NM 011198 +1.5NS −1.1NS −3.1
S100 calcium binding protein A8 S100A8 NM 013650 +8.9 +1.4NS −2.8
Secretory leukocyte peptidase inhibitor SLPI NM 011414 +6.0 +1.7 −1.1NS
Tumor necrosis factor, alpha TNF NM 013693 +2.3 −1.1NS −1.5
Tumor necrosis factor receptor superfamily,
member 1B
TNFRSF1B NM 011610 +1.9 −1.3 −1.3NS
Data represent the fold-change in gene expression for the particular comparison, calculated using limma analysis according to the Bioconductor
framework and clustered in pathways according the Ingenuity Pathway Analysis Software. Total RNA from colon tissue was used for microarray
hybridization to Agilent Technologies 44k (G4122-60510) mouse 60mer oligonucleotide arrays. A NS superscript means the reported fold-change
was not significant between the two groups being compared. For the inoculation (EF·CIF-inoculated IL10−/− vs. similarly treated C57 mice) and
PUFA (PUFA-fed IL10−/− vs. AIN-76A-fed IL10−/− mice) experiments data represent mean values from two pools of RNA for each mouse strain,
with RNA from two and three mice, respectively, in each pool.
Gene expression analysis using limma and pathway
clustering using Ingenuity Pathway Analysis Software
revealed ‘cell-to-cell signaling and interaction’, ‘inflam-
matory diseases’ and ‘amino acid metabolism’ as the
key functions affected in IL10−/− mice fed EPA- and
AA-enriched diets (Table 3). This paper focused on the
expression data for genes in the ranked first 1000 list
that are significant according to the criteria stated in Sec-
tion 2.7 and that clustered in the ‘immune response’ and
‘inflammatory diseases’ pathways (Table 4). The gene
list for EF·CIF IL10−/− versus C57 comparison pre-
sented in Table 4 is data from the inoculation trial as
similar results were obtained from the PUFA trial for
that comparison.
3.3. Specific differentially expressed genes in the
inoculation or PUFA trial
The expression of the monoglyceride lipase gene
(MGLL) which is involved in lipid metabolism and
inflammatory responses was down-regulated in IL10−/−
mice compared to C57 mice, both fed the control diet but
MGLL expression was up-regulated in the IL10−/− mice
fed PUFA diets (Table 4). The S100A8 protein plays a
role in inflammatory responses and its gene expression
was up-regulated by 8.9-fold in IL10−/− mice fed the
control diet compared to C57 mice fed the same diet.
In contrast, the expression of the S100A8 gene showed
a significant down-regulation in the IL10−/− mice fed
the AA-enriched diet, but its expression was unchanged
in the EPA-fed IL10−/− mice (Table 4). The expres-
sion of the prostaglandin-endoperoxide synthase 2 gene
(PTGS2, also named COX-2), which is a major medi-
ator of inflammation, was unchanged in IL10−/− mice
fed the control diet, but when this diet was enriched with
AA, PTGS2 gene expression was down-regulated.
Table 4 also shows which genes involved in innate
immune responses and T-cell responses had altered
expression as a consequence of the dietary PUFA treat-
ments. This includes genes such as tumor necrosis factor
alpha (TNF; only significant for the AA-enriched diet)
and its receptor (tumor necrosis factor receptor super-
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Table 5
‘Antigen presentation pathway’ genes differentially expressed in colon tissue of EF·CIF-inoculated IL-10−/− mice compared with EF·CIF-inoculated
C57 mice
Gene name Symbol Refseq ID EF·CIF IL10−/−
vs. EF·CIF C57
CD74 molecule, MHC Class II invariant chain CD74 NM 010545 +5.7
Histocompatability 2, Q region locus 1 H2-Q1 NM 010390 +1.5
MHC Class II, DM alpha HLA-DMA NM 010386 +2.9
MHC Class II, DM beta HLA-DMB NM 010387 +7.1
MHC Class II, DQ alpha 1 HLA-DQA1 NM 010378 +4.4
MHC Class II, DQ beta 2 HLA-DQB2 NM 207105 +6.3
MHC Class II, DR beta 1 HLA-DRB1 NM 010382 +4.6
HLA-G histocompatability antigen, Class I, G HLA-G NM 010391 +1.8
Proteasome (prosome, macropain) subunit, beta type, 8
(large multifunctional peptidase 7)
PSMB8 NM 010724 +3.9
Proteasome (prosome, macropain) subunit, beta type, 9
(large multifunctional peptidase 2)
PSMB9 NM 013585 +3.8
Transporter 1, ATP-binding cassette, sub-family B TAP1 NM 013683 +2.5
Transporter 1, ATP-binding cassette, sub-family B TAP2 NM 011530 +1.7
Data represent the fold-change of gene expression for the particular comparison, calculated using limma analysis according to the Bioconductor
framework and clustered in pathways using Ingenuity Pathway Analysis Software. Total RNA from colon tissue was used for microarray hybridization
to Agilent Technologies 44k (G4122-60510) mouse 60mer oligonucleotide arrays. Data represent mean values from two pools of RNA for each
mouse strain, with RNA from two and three mice, respectively, in each pool.
family, member 1B (TNFRF1B); only significant for
the EPA-enriched diet), which were over-expressed in
IL10−/− mice fed the control diet compared to C57 mice
fed the same diet, but under-expressed in IL10−/− mice
fed either PUFA diet (Table 4). There was no change in
interleukin 6 (IL6) expression in IL10−/− mice fed the
control diet, but this gene showed a lower expression
in mice fed the AA-enriched diet (not statistically
significant for the EPA-enriched diet). The secretory
leukocyte peptidase inhibitor (SLPI) gene, expression
of which was up-regulated by 6-fold in IL10−/− mice
compared to C57 mice, was still up-regulated but by
only 1.7-fold in IL10−/− mice fed the EPA-enriched
diet, but decreased in IL10−/− mice fed the AA-enriched
diet. The expression of the inducible T-cell costimulator
ligand (ICOSLG) gene was unchanged in the IL10−/−
mice fed the control diet, but up-regulated in IL10−/−
mice fed the PUFA diets (Table 4).
Other genes involved in immune response and inflam-
mation that were up-regulated in IL10−/− mice fed either
PUFA-enriched diet were the ABCB4 gene (also named
multidrug resistance gene 2 (mouse); down-regulated in
IL10−/− mice compared to C57 mice fed the control
diet) and the PPAR gene (Table 3). The other isoform of
the PPAR gene, PPAR, was down-regulated in IL10−/−
mice fed the control diet but unchanged with the PUFA-
enriched diet (data not shown). In contrast, myosin
light polypeptide kinase (MYLC) and protease serine
23 genes were under-expressed in the IL10−/− mice fed
the control diet but over-expressed when the IL10−/−
mice were fed the PUFA diets (Table 4). Expression of
the genes encoding calpastatin and CD38 molecule were
up-regulated irrespective of the strain effect or dietary
PUFAs (Table 4).
4. Discussion
Our study shows for the first time that oral inoc-
ulation of IL10−/− mice (C57 background) with an
EF·CIF bacterial preparation at 5 weeks of age results
in increased and consistent inflammation compared to
non-inoculated IL10−/− mice, with the most highly
inflamed area of intestine being the colon. These
histological changes were accompanied by significant
changes in expression of genes involved in ‘immune
response’, ‘inflammatory diseases’ and ‘antigen presen-
tation’ by 11 weeks of age. These results support the
suggestion that our refined IL10−/− mouse model shows
characteristics of chronic inflammatory diseases, such as
a dysregulated immune response acting in combination
with inflammatory mechanisms that can cause tissue
damage. The up-regulation of antigen presentation genes
is consistent with increased expression of HLA Class II
molecules that typically occurs in IBD in humans [29].
HLA Class II genes have been associated with risk of
IBD in a number of populations [30,31] (reviewed in
ref. [32]). In addition, MHC Class II antigen expression
N. Roy et al. / Mutation Research 622 (2007) 103–116 113
Fig. 3. (a) Total intestinal histological injury score (HIS) and (b)
colonic HIS of IL10−/− and C57BL/6J mice at 11 weeks of age after
PUFA treatments from 5 to 11 weeks of age. Data represent means for
6 mice fed AIN-76A diet, or AIN-76A diet supplemented with oleic
acid (OA) or the PUFAs eicosapentaenoic acid (EPA) or arachidonic
acid (AA). AIN-76A and OA are both control diets. Bars represent
the least significant differences (LSD) for each mouse strain. All mice
were inoculated at 5 weeks of age with a combination of 12 Enteroc-
cocus strains and conventional intestinal flora from normal C57BL/6
mice.
has previously been observed in the colon epithelial
cells of 3–6 month-old IL10−/− mice [16]. Overall, our
findings indicate that this refined IL10−/− mouse model
represents an improved model of IBD, due to increased
intestinal inflammation as a result of the inoculation
procedure. This model is therefore more suitable for
testing various food components to identify those with
potential beneficial effects for IBD patients.
Using this model, we have shown that dietary EPA
and AA lowered the colonic inflammation observed in
IL10−/− mice. Unexpectedly, both AA- and EPA-fed
IL10−/− mice lost more body weight than IL10−/− mice
fed the control diets (AIN-76A and OA diets), but AA-
fed IL10−/− mice did not lose as much body weight as
those fed EPA. Why growth was reduced with the EPA
diet is unclear. Improved colonic health (occurrence and
incidence of colonic tumors) in Apc(min) mice fed an
EPA-enriched diet similar to this study has also been
reported in the literature [23]. However, in that study, a
similar diet enriched with AA increased the occurrence
and incidence of colonic tumors in these mice compared
to OA-enriched diet [23] whereas we did not observe
similar effects of AA on colonic inflammation.
In IL10−/− mice fed the control diet, expression of
PTGS2, a gene coding for an enzyme that catalyses the
formation of prostaglandins from AA, was unchanged.
This is in contrast with literature reports showing that
PTGS2 is over-expressed in sites of early inflammation
[33]. Results of another study by our group indicated
that EF·CIF IL10−/− mice fed a control diet similar to
the control (AIN-76A) diet used in this study showed
early signs of inflammation at 8 weeks of age [24]
so it is possible that an early increase in PTGS2 gene
expression occurred but did not persist to 11 weeks of
age. When AA-enriched diet was fed to IL-10−/− mice,
expression of the PTGS2 gene was down-regulated at 11
weeks of age. It has been shown in vitro that unsaturated
fatty acids such as EPA are the most potent inhibitors
of AA-induced PTGS2 protein activity [34] and
lipopolysaccharide-induced PTGS2 protein expression
[35]. In Lee et al.’s study, lipopolysaccharide-induced
PTGS2 protein expression was also inhibited by n − 6
PUFA such as AA but to a lesser degree than EPA and
DHA while saturated fatty acids induced its expression
[35]. As PTGS2 catalyses the formation of pro-
inflammatory prostaglandin E2 from AA, higher dietary
AA should induce colonic inflammation but this was not
the observation in IL10−/− mice fed the AA-enriched
diet. Why AA reduced the colonic expression of PTGS2
and inflammation in IL10−/− mice in this study is
unclear. It has been shown that prostaglandin E2 also
suppresses production of TNF and IL6 by monocytes
and macrophages, and inhibits 5-lipoxygenase, thereby
interfering with leukotriene X4 production; in this way,
AA could give rise to anti-inflammatory lipoxins [36].
In IL10−/− mice fed the control diet, there was a
four-fold down-regulation of ABCB4 in colonic tissues.
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Another gene which is part of the ABC family, ABCB1,
was also down-regulated in the same mice (data not
shown). Like several other ABC transporters, ABCB4 is
a lipid translocator and it has been shown to translocate
phosphatidylcholine from the inner to the outer leaflet
of the canalicular membrane of hepatocytes; ABCB4
deficiency results in severe liver disease [37]. In colonic
tissue, to our knowledge, there is no report of ABCB4
gene expression in the literature. As in this study, chronic
colonic inflammation as observed in IBD patients and in
animal models of IBD can result in a down-regulation
of other ABC genes, such as ABCB1A and ABCB1B
[38–40] suggesting a dysregulation of the ABC trans-
porters during inflammation. In contrast, PUFA-enriched
diets resulted in an up-regulation of the ABCB4 gene and
likely, in a more optimal lipid translocation.
Furthermore, the expression of the S100A8 gene that
codes for a calcium binding protein was up-regulated
by nine-fold in IL10−/− mice fed the control diet.
Murine S100A8 is a potent chemo-attractant (calcium
binding protein) and its up-regulation has been associ-
ated with a number of acute and chronic inflammatory
conditions and may protect against oxidative tissue
damage [41]. In contrast, the down-regulation of the
S100A8 gene observed in IL10−/− mice fed the AA
diet could be explained by the additional free extra-
cellular AA available to the inflamed tissue reducing
the need for intracellular AA to be transported through
the S100A8/A9-AA complex at the site of inflammatory
lesions [42].
Down-regulation of the expression of FGF7 (also
called keratinocyte growth factor) was observed in the
colon of IL10−/− mice fed AA-enriched diet but its
expression was unchanged in the colon of IL10−/−
and C57 mice fed the control diet. FGF7 is involved
in epithelial regeneration, and could be less active in
IL10−/− mice fed AA because of the reduced colonic
inflammation and tissue damage observed in this diet
group, indicating a reduced requirement for regenera-
tion. No mRNA for the FGF7 gene was detected in colon
of dextran sodium sulfate challenged pigs (another
model of IBD) fed a control diet or diets supplemented
with n − 3 PUFA (no data was available for n − 6 PUFA)
despite increased colonic tissue regeneration [43]. This
result indicates that epithelial regeneration may in this
case be FGF7-independent although its occurrence
might depend on other growth factors and cytokines
[44]. In the Bassaganya-Riera and Hontecillas study
[43], an n − 3 PUFA-enriched diet failed to protect
from IBD, and instead promoted remission from IBD
possibly by activating PPAR. The same study showed
that a mixture of conjugated linoleic acid and n − 3
PUFAs accelerated recovery from IBD by activating
PPAR and up-regulating the expression of FGF7 in
the colon, while CLA alone delayed the onset of IBD
by activating another isoform of PPAR, PPAR. These
results together might indicate a synergistic regulation
of inflammatory pathways by unsaturated lipids.
The colonic expression of PPAR was down-
regulated by at least two-fold in IL10−/− mice fed
the control diet but up-regulated when fed the PUFA-
enriched diets. PPAR molecules have three isoforms
(, , ) and act as a sensor for intracellular nutrient
concentration through a nuclear receptor, thus regu-
lating gene expression [36]. Up-regulation of PPAR
by AA corroborates previous findings where PPAR
isoforms in the intestine can be activated by PUFAs to
ameliorate inflammatory disease severity [43]. PPAR
gene activation is not specific to PUFA as a large
number of fatty acids have been shown to activate this
gene [36]. PPAR genes can be activated by lipids or
their metabolites (e.g. oxidized phospholipids, raised
AA concentrations or eicosanoids) following binding
to the PPAR receptor [36]. For example, PPAR could
have been activated indirectly through the increased AA
concentration as a result of feeding the AA-enriched
diet, or because of eicosanoid formation from AA via
the CYP4A family [45], although the expression of
the genes coding for the CYP4As was unchanged in
IL10−/− mice fed this diet (data not shown). In contrast
to PPAR, PPAR has selectivity for unsaturated fatty
acids including PUFAs [36]. However, in IL10−/−
mice fed PUFA-enriched diet, PPAR expression was
unchanged.
The beneficial effect of PUFAs on colonic inflamma-
tory responses seen in this study agrees with literature
reports which show that PUFAs have immunomo-
dulatory effects on cells of the immune system [36].
The results from the current study therefore suggest
that, contrary to the proposed hypothesis, dietary AA
supplementation had a beneficial effect on intestinal
inflammation similar to that of EPA, and showed si-
milar gene expression results to those of CLA reported
in inflamed pigs [43]. AA activated colonic PPAR but
also diminished the production of genes involved in
immunomodulation and inflammation (TNF, IL6, etc.).
Comparing gene expression changes in tissues of ani-
mals fed n − 3 versus n − 6 PUFAs diets often reveals
only minor differences [36]. However, the preliminary
results from this study suggest that the refined mouse
model of IBD developed here, IL10−/− mice inoculated
with EF·CIF, allows important gene expression changes
occurring as a result of n − 3 and n − 6 PUFA-enriched
diets to be identified.
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5. Conclusions
The studies described in this paper show the deve-
lopment of an improved mouse model of inflammation,
and one example of using this model to investigate food
components with potential for the amelioration of IBD.
These results represent early steps in the development
of foods which may interact with an individual’s genetic
make-up in a beneficial manner, to improve health and
well-being.
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